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Abstract
Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective
and well-tolerated treatment option for patients with breast cancer. Bevacizumab has demonstrated a gain in
progression-free survival and a trend towards an overall survival benefit in various subgroups of breast cancer.
Given the lack of a predictive biomarker, we performed a literature search with regard to efficacy and tolerability of
bevacizumab in different subgroups of breast cancer patients and in different settings. In the metastatic setting, the
efficacy of bevacizumab has been most extensively studied and demonstrated in patients with triple-negative
breast cancer, the most difficult-to-treat population among patients with advanced disease and also the group with
the biggest need for new treatment options. Overall, bevacizumab is well tolerated with very few serious adverse
events. Bevacizumab is also an active and feasible treatment option for patients above 70 years of age.
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Introduction
Breast cancer (BC) is a heterogeneous disease with varied
molecular features, morphological subtypes, and differen-
tial response to therapy. Standard treatment for metastatic
breast cancer (MBC) is hormonal therapy or chemother-
apy. Approximately 20–25% of early-stage BCs over-
express human epidermal growth factor receptor 2
(HER2) and can be treated with HER2-targeted agents
(e.g., trastuzumab and lapatinib) (Pegram et al. 1998). The
most active chemotherapeutic agents are taxanes and
anthracyclines, with activity also seen with vinorelbine,
capecitabine, gemcitabine, and eribulin (Lohman & Chia
2012). The combination of anti-angiogenic agents (e.g.,
bevacizumab) with chemotherapy has demonstrated lon-
ger progression-free survival (PFS) with acceptable
toxicity.
Angiogenesis is critical for tumor growth and the de-
velopment of metastatic disease. Vascular endothelial
growth factor (VEGF) is an angiogenic mediator that
stimulates endothelial cell proliferation and migration;
inhibits endothelial cell apoptosis; induces extracellular
matrix remodeling; increases vascular permeability; and
inhibits antigen-presenting dendritic cells. Tumors with
enhanced angiogenesis, supporting rapid growth and
early metastases (e.g., triple-negative breast cancer
[TNBC]), have high levels of VEGF (Greenberg & Rugo
2010).
Bevacizumab (Genentech Inc, CA, U.S.) is a humanized
monoclonal antibody against all VEGF-A isoforms.
Bevacizumab prevents binding of VEGF to receptors on
vascular endothelial cells, leading to inhibition of angio-
genesis and tumor growth. A Phase I/II clinical trial inves-
tigated 3, 10, or 20 mg/kg of bevacizumab monotherapy
in patients with previously treated MBC. The objective
response rate (ORR) was 9.3%, and 17% of patients had a
response or were stable at 22 weeks; 10 mg/kg was sug-
gested for further trials (Cobleigh et al. 2003).
Bevacizumab may also potentiate the effect of chemother-
apy regimens.
Search strategy
English language reports of bevacizumab clinical trials in
BC were identified by searching PubMed and the
* Correspondence: vibeke.kruse@uzgent.be
1Department of Medical Oncology, University Hospital Ghent, De Pintelaan
185, 9000, Ghent, Belgium
2Heymans Institute of Pharmacology, University of Ghent, Ghent, Belgium
Full list of author information is available at the end of the article
a SpringerOpen Journal
© 2013 Kruse et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Kruse et al. SpringerPlus 2013, 2:202
http://www.springerplus.com/content/2/1/202
American Society of Clinical Oncology and European
Society of Medical Oncology databases using the follow-
ing terms: ‘bevacizumab’ and ‘breast cancer’ or ‘toler-
ance’ or ‘chemotherapy’ or ‘review’ or ‘safety’ or
‘angiogenesis’. Additional relevant studies were found
via bibliographic review of reports identified during
the systematic search. Studies in patients with locally
recurrent (LR) or MBC who received bevacizumab in
combination with standard chemotherapy with an ap-
propriate trial design, appropriate statistical method-
ology, and a sufficient number of patients were
included, as well as relevant pharmacodynamic and
pharmacokinetic data.
Results
Data selection
We identified 14 papers presenting data from large, ran-
domized, Phase III trials and two papers presenting data
from Phase I/II trials on bevacizumab in BC. We also
refer to three abstracts presented at The Annual San
Antonio Breast Cancer Symposium and The Annual
Congress of the European Society for Medical Oncology,
including data from two meta-analyses. Furthermore, we
selected one Cochrane Review, one pooled analysis of
bevacizumab efficacy, and one National Cancer Institute
report on bevacizumab in BC. We also identified 13 re-
views on safety, pathological issues, angiogenesis, and
biomarker considerations with respect to bevacizumab.
First-line HER2-negative LR/MBC
In the first-line setting, E2100 (n = 685) demonstrated sig-
nificant PFS and ORR improvements with paclitaxel plus
bevacizumab compared with paclitaxel alone among pa-
tients with HER2-negative LR/MBC (Miller et al. 2007).
Median PFS was approximately 11.4 months with the
combination versus 5.8 months with paclitaxel alone
(Gray et al. 2009). ORR was also significantly higher with
paclitaxel-bevacizumab than with paclitaxel alone (48.0%
vs. 23.4%, P < 0.0001) (Gray et al. 2009). These results
were validated by independent review (Gray et al. 2009).
The AVADO trial (n = 736) evaluated the efficacy and
safety of bevacizumab (7.5 and 15 mg/kg) plus docetaxel
as first-line therapy for HER2-negative, LR/MBC (Miles
et al. 2010a). Bevacizumab (15 mg/kg) plus docetaxel
showed a 1.9-month (P = 0.06) improvement in median
PFS compared with placebo plus docetaxel. Response
rates in patients with measurable disease at baseline were
also increased with bevacizumab (46% with placebo vs.
55% with bevacizumab 7.5 mg/kg [P = 0.07] and 64%
with bevacizumab 15 mg/kg [P < 0.001]). In the RIBBON-
1 trial (n = 1,237), the combination of bevacizumab
with capecitabine, taxane-based, or anthracycline-based
chemotherapy was evaluated as first-line treatment for
HER2-negative MBC (Robert et al. 2011). Median PFS was
longer for each bevacizumab-chemotherapy combination
compared with placebo-chemotherapy, and was most pro-
nounced in the capecitabine cohort where PFS increased
from 5.7 months to 8.6 months (P = 0.0002). ORR in pa-
tients with measurable disease was significantly higher in
the bevacizumab-containing arm compared with the pla-
cebo arm for each chemotherapy cohort. There was no sig-
nificant difference in overall survival (OS) between the
placebo- and bevacizumab-containing arms (Robert et al.
2011). The ATHENA trial (n = 2,251) evaluated the efficacy
of bevacizumab in combination with taxane-based chemo-
therapy in routine oncology practice (Smith et al. 2011).
Median treatment duration was 6.2 months (range 0.0–
29.7) for bevacizumab and 4.2 months (range 0.0–29.5) for
chemotherapy. The median time to progression (TTP) was
9.5 months (95% confidence interval [CI] 9.1 − 9.9). ORR
(best response) was 52% in the intent-to-treat (ITT) popula-
tion. A further 33% of patients achieved stable disease
(Smith et al. 2011). Mature data from ATHENA demon-
strated a median OS of 25.2 months in patients receiving
bevacizumab plus standard first-line chemotherapy
(Pritchard et al. 2010). Patients continuing single-agent
bevacizumab until disease progression after stopping
chemotherapy showed a median TTP of 11.6 months with
median OS of 30.0 months. There was no relationship
detected between development of hypertension and OS
(Pritchard et al. 2010).
Second-line HER2-negative LR/MBC
Several trials have investigated bevacizumab for previously
treated MBC. RIBBON-2 (n = 684) evaluated the efficacy
and safety of bevacizumab plus commonly used chemo-
therapies for the second-line treatment of MBC (Brufsky
et al. 2011). Bevacizumab plus chemotherapy increased
median PFS from 5.1 to 7.2 months (hazard ratio [HR]
0.78, 95% CI 0.64 − 0.93, P = 0.0072) and reduced the risk
of death by 22% (HR 0.78, 95% CI 0.64 − 0.93, log rank
P = 0.0072). The ORR improvement between the placebo-
and bevacizumab-containing arms (39.5% and 29.6%, re-
spectively; not significant) was consistent with previous
trials. Results of the earlier AVF2119g trial are less encour-
aging (Miller et al. 2005). The AVF2119g trial evaluated
the combination of bevacizumab with capecitabine, but
failed to meet its primary endpoint of prolonged PFS
(median 4.9 vs. 4.2 months for bevacizumab-capecitabine
compared with capecitabine alone, respectively; HR 0.98).
However, patients included in the AVF2119g study had a
poor prognosis (Miller et al. 2005).
Subgroup analyses
Phase III trials have established consistent improvements
in PFS by combining bevacizumab with chemotherapy
as first-line treatment for MBC. Improved PFS was also
seen in the second-line setting. However, to date all
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trials have failed to demonstrate a clear survival benefit.
We reviewed the subgroup analyses of the trials to de-
tect which patients would most benefit from the
addition of bevacizumab treatment.
TNBC (HER2-negative, estrogen-/progesterone-receptor
negative)
The prognosis for patients with metastatic TNBC is typ-
ically poor and there is no established standard therapy.
Taxane-based regimens are among the most active and
represent a reasonable approach for TNBC patients with
a high risk of relapse.
A meta-analysis of TNBC patients in the randomized
E2100, AVADO, and RIBBON-1 trials (n = 363 treated
with bevacizumab plus chemotherapy, n = 258 treated
with chemotherapy alone) showed a significant improve-
ment in PFS for patients treated with chemotherapy plus
bevacizumab (O’Shaughnessy et al. 2010). Median PFS was
8.1 months with bevacizumab-containing therapy versus
5.4 months for chemotherapy alone (HR 0.680, P = 0.0002).
The PFS benefit remained when the patient subgroups
(disease-free interval ≤24 months vs. >24 months;
number of metastatic sites <3 vs. ≥3; the presence or
not of visceral metastases) were assessed. ORR was sig-
nificantly higher with bevacizumab-containing therapy
than with chemotherapy alone (42% vs. 23%, P < 0.0001)
(O’Shaughnessy et al. 2010).
An exploratory subgroup analysis of TNBC patients
treated during routine oncology practice in the
ATHENA study confirmed that the combination of
paclitaxel-bevacizumab was active. In this subgroup, the
median TTP was 7.2 months (95% CI 6.6 − 7.8) and the
ORR was 49%, with a complete response (CR) rate of
10%. The 1-year OS rate was 60%. Median OS was
18.3 months (TNBC subgroup; 95% CI 16.4–19.7),
27.3 months (non-TNBC subgroup), and 25.2 months
(overall population) (Thomssen et al. 2012). Updated
survival results demonstrated a median OS of
18.3 months in patients with TNBC.
A subgroup analysis of the RIBBON-2 trial of
TNBC patients who had progressed on first-line non-
bevacizumab-containing chemotherapy also revealed a
significant benefit of adding bevacizumab to standard
second-line chemotherapy (Brufsky et al. 2012). Median
PFS was 6.0 months with bevacizumab-chemotherapy
versus 2.7 months with chemotherapy alone (HR 0.494,
95% CI 0.33 − 0.74, P = 0.0006). ORR was 41% vs. 18%,
respectively, (P = 0.0078). Despite the small sample size
and immature data, there was a trend towards improved
OS: 17.9 months versus 12.6 months, respectively (HR
0.624, 95% CI 0.39 − 1.007, P = 0.0534).
The safety profile of bevacizumab in the TNBC sub-
group was consistent with previous reports.
Elderly patients with HER2-negative MBC
The AVADO trial included 127 elderly (≥65 years) pa-
tients with HER2-negative MBC (Pivot et al. 2011). PFS
was increased with bevacizumab therapy in the elderly
subpopulation, the effect being greater with the 15 mg/
kg dose but not statistically significant (PFS 10.1 months
vs. 7.7 months with 7.5 mg/kg, HR 0.68, 95% CI 0.428 −
1.076). PFS data were generally consistent with the over-
all study population. Elderly patients with measurable
disease at baseline had a higher ORR with bevacizumab
plus docetaxel compared with placebo plus docetaxel
(50%, 95% CI 35.2 − 64.8 vs. 44.7%, 95% CI 28.6 − 61.5).
In the overall ITT population, response rates were
higher than in the elderly ITT subpopulation, with the
higher dose bevacizumab (15 mg/kg) arm being statisti-
cally superior to the placebo group (64.1% vs. 46.6%,
P < 0.001). For the 1-year survival rates, there was a sta-
tistically significant treatment effect for the overall
bevacizumab ITT population versus the ITT placebo popu-
lation (84% vs. 76%, respectively, P < 0.02). The safety profile
of bevacizumab was consistent in the overall and elderly
populations (Pivot et al. 2011). Given the risk of arterial
thromboembolic events with bevacizumab, it has been
recommended that patients aged ≥65 years receive prophy-
lactic low-dose aspirin (Hamilton & Blackwell 2011).
The elderly subpopulation of the ATHENA study
comprised 175 patients aged ≥70 years (Biganzoli et al.
2012). Almost half of the elderly patients (46%) received
paclitaxel plus bevacizumab. Median TTP was 10.4 months
among elderly patients compared with 9.5 months
(95% CI 9.1 − 9.9) in the overall ITT population. ORR
was 42% for the elderly patients and 52% in the overall
ITT population. The combination was well tolerated by
elderly patients. Only hypertension and proteinuria
were more common in older than in younger patients
(Grade ≥3 hypertension: 6.9% vs. 4.2%, respectively;
Grade ≥3 proteinuria: 4.0% vs. 1.5%, respectively)
(Biganzoli et al. 2012). Updated survival results showed
a median OS of 20.4 months for elderly patients treated
with combination therapy. Adverse events (AEs) of
bevacizumab among patients aged ≥70 years versus pa-
tients aged <70 years are presented (Table 1) (Biganzoli
et al. 2012).
Patients pretreated with taxanes for HER2-negative MBC
An exploratory analysis of data from the subpopulation of
taxane-pretreated patients re-exposed to taxanes in the
E2100 and AVADO trials (n= 311), with or without
bevacizumab, demonstrated a benefit of adding bevacizumab
(Miles et al. 2010b). Median PFS was 10.7 months with
bevacizumab-taxane combination therapy versus 6.2 months
with taxane alone (HR 0.533, P= 0.0001). The ORR was also
significantly higher with combination therapy than with
taxane monotherapy (49% vs. 27%; P < 0.005). OS was
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superior in patients receiving bevacizumab-taxane combin-
ation therapy; this was pronounced in the TNBC patient
population with an OS of 25.6 months for taxane-
bevacizumab therapy versus 15 months with taxane alone
(HR 0.61; P= 0.0247). Despite promising results, this analysis
has some limitations, notably a lack of stratification for
taxane pretreatment in the E2100 trial and a limited number
of taxane-pretreated patients in the AVADO trial receiving
standard dose bevacizumab (n= 77). Furthermore, none of
these trials was powered to show an OS benefit. However,
the data suggest that patients previously treated with a
taxane can benefit from retreatment with a taxane in
combination with bevacizumab (Miles et al. 2010b). This
might be valuable information, especially for patients with
poor prognosis, such as those with TNBC.
The safety profile of bevacizumab in taxane-pretreated
patients was consistent with the well-defined safety
profile of bevacizumab in combination with taxane
therapy.
HER2-positive BC
Recently, Phase II data were presented from an open-
label study evaluating the efficacy and safety of
bevacizumab in combination with trastuzumab and
Table 1 Grade 3 to 5 adverse events of special interest in patients aged ≥70 years versus patients aged <70 years in
the ATHENA trial (Biganzoli et al. 2012) [Permission required for reproduction]
Age <70 years (n = 2,076), % Age ≥70 years (n = 175), %
On treatment Entire study period On treatment Entire study period
Hypertension 3.2 4.2 5.1 6.9
Grade 3 3.1 4.0 4.6 6.3
Grade 4 <0.1 0.1 0.6 0.6
ATE/VTE 1.2 3.3 0.6 2.9
Grade 3 1.2 2.4 0.6 0.6
Grade 4 0 0.7 0 1.7
Grade 5 0 0.2 0 0.6
Proteinuria 1.0 1.5 2.3 4.0
Grade 3 1.0 1.4 2.3 2.9
Grade 4 0 0.1 0 1.1
Other hemorrhage 0.3 1.4 1.1 1.1
Grade 3 0.2 1.1 1.1 1.1
Grade 4 <0.1 0.2 0 0
Grade 5 0 0.1 0 0
Wound healing complications 0.3 0.6 0.6 1.1
Grade 3 0.2 0.3 0 0.6
Grade 4 0.1 0.2 0.6 0.6
Congestive heart failure 0.1 0.4 0 0.6
Grade 3 0.1 0.3 0 0
Grade 4 <0.1 <0.1 0 0
Grade 5 0 0.1 0 0.6
Gastrointestinal perforation 0 0.3 0 0
Grade 3 0 0.1 0 0
Grade 4 0 <0.1 0 0
Grade 5 0 0.1 0 0
Fistulae 0 0.1 0 0
Grade 3 0 0.1 0 0
CNS bleeding 0 <0.1 0 0
Grade 5 0 <0.1 0 0
AVE/VTE arterial or venous thromboembolism, CNS central nervous system.
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capecitabine as first-line therapy for HER2-positive LR/
MBC. A total of 88 patients were enrolled and 40 were
still on treatment at the time of reporting (Martin et al.
2012). Patients received bevacizumab (15 mg/kg on day
1) plus trastuzumab (8 mg/kg on day 1 of cycle 1, 6 mg/
kg on day 1 of subsequent cycles) plus capecitabine
(1,000 mg/m2 twice daily, days 1–14) every 3 weeks. The
ORR (primary endpoint) was 73% (95% CI 62–82), com-
prising a CR and partial response rate of 7% and 66%, re-
spectively. Median PFS was 14.4 months (95% CI 10.4− not
reached) with 33 events. Overall, 44% of patients experi-
enced Grade ≥3 treatment-related AEs, and three patients
discontinued capecitabine because of toxicity but continued
with bevacizumab and trastuzumab. The combination of
trastuzumab, bevacizumab, and capecitabine seems to be
clinically active as first-line therapy for patients with HER2-
positive LR/MBC (Martin et al. 2012). Ongoing Phase I and
II trials are evaluating this combination.
Neoadjuvant treatment of HER2-negative and HER2-positive
BC
GeparQuinto was a Phase III study evaluating bevacizumab
in the neoadjuvant setting (von Minckwitz et al. 2012). In
the HER2-negative component of this study, 1,948 patients
were enrolled. A total of 144 patients (14.9%) who received
epirubicin-cyclophosphamide followed by docetaxel and 176
patients (18.4%) treated with epirubicin-cyclophosphamide
followed by docetaxel-bevacizumab had a pathological CR
(pCR; pathological stage T0N0) (odds ratio with the addition
of bevacizumab, 1.29, 95% CI 1.02 − 1.77, P = 0.04). The
pCR achieved with the addition of bevacizumab increased
to 20.5% if nodal involvement was included in the definition,
to 21.7% if non-invasive residual disease in the breast was
included, and to 24.6% if both were included. Among 663
patients with triple-negative tumors, the rates of pCR
were 27.9% in the group that received epirubicin-
cyclophosphamide followed by docetaxel and 39.3% in
the group that received epirubicin-cyclophosphamide
followed by docetaxel-bevacizumab (P = 0.003). Among
1,262 patients with hormone receptor-positive tumors,
corresponding pCR rates were 7.8% and 7.7% (P = 1.00).
The overall clinical response rate was higher in the
bevacizumab group (87.4% vs. 79.6%), whilst the rate of
breast-conserving surgery was identical in both groups
(66.6%). A 4-week interval between the last bevacizumab
dose and surgery was sufficient to reduce the incidence of
therapy-associated surgical complications. Given the short
follow-up period, these data cannot confirm that the ob-
served increase in the rate of pCR can be translated into a
survival advantage (von Minckwitz et al. 2012).
Similar results were seen in a study of patients with
HER2-negative BC (n = 1,206), which investigated the ef-
fect of adding capecitabine or gemcitabine to docetaxel,
compared with docetaxel alone, for four cycles, followed
by treatment with doxorubicin-cyclophosphamide for
four cycles with or without bevacizumab (15 mg/kg) for
the first six cycles of chemotherapy (Bear et al. 2012).
The addition of capecitabine or gemcitabine to
docetaxel, compared with docetaxel alone, did not sig-
nificantly increase the pCR rate (29.7% and 31.8%, re-
spectively, vs. 32.7%; P = 0.69); while the addition of
bevacizumab significantly increased pCR rate (28.2%
without vs. 34.5% with bevacizumab; P = 0.02). The ef-
fect of bevacizumab was more pronounced in the hor-
mone receptor-positive subset (15.1% without vs. 23.2%
with bevacizumab; P = 0.007), with a weaker effect in the
hormone receptor-negative subset (triple negative). The
pCR rate was significantly increased when bevacizumab
was added to docetaxel-capecitabine (36.1% vs. 23.5%;
P = 0.009), but not when it was added to docetaxel-
gemcitabine (35.8% vs. 27.6%; P = 0.10) or docetaxel
alone (31.6% vs. 33.7%; P = 0.75). The addition of
capecitabine or gemcitabine to docetaxel increased the
overall AE rate as did the addition of bevacizumab to
chemotherapy, particularly rates of hypertension,
mucositis, and hand-foot syndrome (Bear et al. 2012).
Bevacizumab plus trastuzumab plus chemotherapy for
primary inflammatory HER2-positive BC was evaluated in a
Phase II, open-label, single-arm trial (BEVERLY-2) in 52 pa-
tients from 21 centers (Pierga et al. 2012). The combination
achieved a pCR in 33 patients (63.5%, 95% CI 49.4 − 77.5).
Neutropenia was the most common Grade 3 or 4 AE. Only
one Grade ≥3 AE was regarded as related to bevacizumab
(hypertension). Based on these results, the use of combin-
ation therapy with bevacizumab appears effective and well
tolerated among patients with previously untreated inflam-
matory BC (Pierga et al. 2012).
The rate of surgical complications in the neoadjuvant
setting was generally low, but was numerically higher in
patients receiving bevacizumab than those who did not.
Wound-healing complications occurred in ≤1.5% of pa-
tients in the bevacizumab arms versus ≤1% in the control
arms. However, patients who undergo surgery ≤28 days
prior to the last dose of bevacizumab have long been ex-
cluded from participating in clinical trials of bevacizumab
(Hamilton & Blackwell 2011).
Discussion
The addition of bevacizumab to chemotherapy has
demonstrated ORR and PFS benefits in the first- and
second-line treatment of MBC. However, according to
a recent Cochrane Review, the overall benefit from
adding bevacizumab to chemotherapy in MBC is con-
sidered modest. Benefits are dependent on the
chemotherapy type and limited to a significant im-
provement in PFS and ORR with first- and second-
line therapy (Wagner et al. 2012). Still, bevacizumab
is an active and feasible treatment option for elderly
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patients and even for patients pretreated with taxanes.
The benefit seems to be most pronounced for pa-
tients with TNBC, the subgroup that typically
experiences the smallest benefit from standard
chemotherapy. A trend towards an OS benefit with
bevacizumab was seen in RIBBON-2 (pretreated pa-
tients) (Brufsky et al. 2012) and ATHENA (patients
not previously treated for metastatic disease)
(Pritchard et al. 2010). The effect on OS was persist-
ent in the TNBC and elderly subgroups, but a clear
OS benefit could not be shown (Thomssen et al.
2012; Biganzoli et al. 2012). However, ATHENA was
a single-arm trial and it is difficult to draw conclu-
sions regarding the impact of combining bevacizumab
with chemotherapy on efficacy. Given the large sam-
ple size (n = 2,251), the trial provides valuable information
on outcomes in clinically important subgroups, such as
patients with TNBC and elderly patients. The lack of a
clear OS benefit is in contrast to results from trials with
bevacizumab in metastatic colorectal cancer where a sig-
nificant difference in ORR, PFS, and OS was seen with
the addition of bevacizumab to standard chemotherapy
(Tappenden et al. 2007).
Preclinical studies have suggested accelerated tumor
growth, local invasion, and distant metastasis after
withdrawal of treatment with some antiangiogenic
agents (Ebos et al. 2009; Pàez-Ribes et al. 2009). This
could explain the lack of OS benefit associated with
bevacizumab. However, a retrospective analysis of five
Phase III, placebo-controlled, randomized trials inves-
tigating the efficacy and safety of bevacizumab in pa-
tients with metastatic breast, renal, colorectal, and
pancreatic cancer does not support a decreased TTP,
increased mortality, or altered disease progression
patterns after cessation of bevacizumab therapy (Miles
et al. 2011).
Bevacizumab has proven efficacy in the neoadjuvant set-
ting; the increased rate of pCR was more pronounced in pa-
tients with hormone receptor-positive tumors. This result is
encouraging, since patients with hormone-positive tumors
tend to have low pCR with chemotherapy (von Minckwitz
et al. 2012). Furthermore, it has been demonstrated that pa-
tients achieving a pCR achieve significantly longer disease-
free survival and OS than non-responders (Feldman et al.
1986; Gralow et al. 2008; Verma et al. 2011).
Only occasionally severe AEs, such as bleeding or
thrombosis (Phase II data), have been associated with
bevacizumab. Overall, bevacizumab is well tolerated
in combination with a range of chemotherapies and
in a broad patient population, including elderly pa-
tients and those with a poor performance status. Data
on bevacizumab-associated quality of life (QoL) are
limited. Only the AVADO trial collected QoL data,
but only to show that the addition of bevacizumab
did not decrease patients’ QoL. Whether there is a
bevacizumab-associated gain in QoL is unclear
(Wagner et al. 2012).
Due to the lack of a clear survival benefit associated
with bevacizumab and no QoL gain, the U.S. Food
and Drug Administration recommended against
bevacizumab in 2010 (National Cancer 2010). The
question of what value PFS has in the context of
MBC was addressed with the recommendation of in-
cluding QoL measurements in future trials. Following
this decision, a discussion regarding appropriate mea-
sures of clinical benefit began. In the era of multiple
lines of subsequent therapy, PFS and TTP should be
considered true endpoints because they are not af-
fected by subsequent lines of chemotherapy. A review
of 73 Phase III trials in MBC revealed that a strik-
ingly small proportion of all trials (n = 9, 12%), and
even fewer first-line trials (n = 4, 8%), demonstrated
OS gains. A model proposed by Broglio and Berry
(Broglio & Berry 2009), based on post-progression
survival (PPS), suggests that with a short median PPS
interval OS is an appropriate primary endpoint, but
with a PPS >12 months it is not because of the
greater likelihood that the effect on OS would be di-
luted by subsequent lines of therapy. This suggests
that OS may be a more appropriate endpoint for
second-line trials in which PPS is shorter, whereas
PFS/TTP may be more appropriate in newly diag-
nosed disease with an expected longer PPS. Extrapo-
lating this model to existing bevacizumab data we
identified a trend towards an OS benefit in RIBBON-
2, the only Phase III trial showing an OS benefit. Re-
garding a possible survival benefit, new data are
awaited.
Given the numerous indications for bevacizumab,
there is a need to investigate and validate putative bio-
markers of efficacy. Concentrations of circulating VEGF
before treatment were not associated with the efficacy of
bevacizumab in an analysis of Phase III clinical trials
(Jubb & Harris 2010). It was proposed that polymor-
phisms in components of the VEGF pathway could be
used to predict benefit from bevacizumab (VEGF-
2578AA and VEGF-1154AA) (Schneider et al. 2008).
However, these data are not clear and have to be con-
firmed before entering clinical practice.
In conclusion, bevacizumab is an active treatment
for patients with MBC. The addition of bevacizumab
has shown a PFS and ORR benefit in the first- and
second-line treatment of MBC, without a clear sur-
vival benefit. To date this effect has been most
extensively studied and demonstrated in the subgroup
of patients with triple-negative disease. Overall,
bevacizumab is well tolerated with very few serious
AEs, even for patients aged >70 years. There is a
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clear need for biomarkers/imaging techniques to as-
sess treatment response and guide treatment, and fu-
ture studies must be conducted.
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